Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

UNITED THERAPEUTICS (UTHR) EBITDA Margin: 2009-2024

Historic EBITDA Margin for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to 47.86%.

  • UNITED THERAPEUTICS's EBITDA Margin rose 278.00% to 48.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 62.63%, marking a year-over-year increase of 1621.00%. This contributed to the annual value of 47.86% for FY2024, which is 305.00% down from last year.
  • As of FY2024, UNITED THERAPEUTICS's EBITDA Margin stood at 47.86%, which was down 6.00% from 50.91% recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's EBITDA Margin ranged from a high of 50.91% in FY2023 and a low of 32.98% during FY2021.
  • Over the past 3 years, UNITED THERAPEUTICS's median EBITDA Margin value was 50.60% (recorded in 2022), while the average stood at 49.79%.
  • In the last 5 years, UNITED THERAPEUTICS's EBITDA Margin soared by 5,297bps in 2020 and then tumbled by 704bps in 2021.
  • Over the past 5 years, UNITED THERAPEUTICS's EBITDA Margin (Yearly) stood at 40.02% in 2020, then crashed by 704bps to 32.98% in 2021, then surged by 1,762bps to 50.60% in 2022, then skyrocketed by 31bps to 50.91% in 2023, then plummeted by 305bps to 47.86% in 2024.